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Measuring glomerular filtration rate using 51Cr-EDTA: body
surface area normalization before or after
Bröchner-Mortensen correction?
Hans Pottela, Liesbeth Hostea, Liesbeth De Waeleb,c, Elke Braatd,f,
Kristof Baetee,g, Karolien Goffine,g, Elena Levtchenkod,f and Olivier Gheysense,g
Background Guidelines for measuring glomerular filtration
rate (GFR) using 51Cr-EDTA require normalizing of GFR for
body surface area (BSA) before applying the Bröchner-
Mortensen (BM) correction. The guideline explicitly
mentions the importance of performing BSA normalization
before BM correction and that this is particularly important
in children in whom the effects of BSA normalization are
largest.
Materials and methods We theoretically showed that the
order of applying BM correction and BSA indexing is indeed
important for patient populations having a low BSA and a
high slow GFR. We then compared the exact GFR, obtained
from the double-exponential concentration–time curve in
Duchenne muscular dystrophy (DMD) patients, with the
GFR obtained from the slow compartment method using
the BM correction.
Results The median GFR for the 20 DMD patients obtained
from the BSA-BM order deviates 5.40% from the exact GFR
(P= 0.0006), whereas the median GFR obtained from the
BM-BSA order deviates only − 0.05% (P> 0.05) from the
exact GFR, resulting in a median of differences of 5.50%
between the two methods (P< 0.0001).
Conclusion The correct order of application in this DMD
population should be BM correction first, followed by BSA
indexing, and not vice versa. In general, the order of applying
the BM correction and BSA normalization becomes more
important with increasing slow GFR and extreme low BSA.
The order of application is of less importance for people
with normal BSA and/or normal GFR. Nucl Med Commun
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Introduction
Renal inulin clearance, performed by loading and con-
tinuously infusing inulin and collecting timed urine
samples through a bladder catheter, is the gold standard
for measuring glomerular filtration rate (GFR) [1]. As
inulin is no longer readily available and this method
requires extensive technical assistance, alternative
methods using radioactive agents, such as 51Cr-EDTA,
99mTc-diethylenetriaminepentaacetic acid, 125I or
131I-iothalamate, are applied as surrogate markers of
GFR. There are, however, problems with each of these
agents: 51Cr-EDTA is not available in the USA; the renal
handling of 99mTc-diethylenetriaminepentaacetic acid
can vary depending on the commercial source, and
131I-iothalamate is readily secreted by the kidney [2]. In
general, these agents are given by a single bolus injection
and the clearance from the blood is measured through
serial blood sampling. GFR is then calculated based on
the area under the plasma clearance curve (AUC) of a
mathematical fit through the data points. Several meth-
ods can be applied to obtain the clearance curve. The rate
of tracer clearance can be best described by a double-
exponential decay curve, leading to the most accurate
determination of both the fast and the slow decaying part.
This double-exponential decay curve, however, requires
up to nine blood samples, which makes it less convenient
in daily clinical practice. Therefore, alternative simplified
sampling strategies have been proposed to determine the
slow decay compartment only. This one-compartment
clearance is fitted with a monoexponential decay function
and allows the calculation of the so-called slow GFR.
This slow GFR overestimates the true GFR, because the
early fast – but missing – compartment cannot be inte-
grated, leading to the underestimation of the AUC. The
overestimation is small (even negligible) for low renal
function but increases nonlinearly with higher and nor-
mal renal function. The overestimation of the true GFR,
or, more exactly, the underestimation of the AUC, can be
corrected using the Bröchner-Mortensen (BM) formula,
or with variants of that correction [3–5].The work was performed in UZ Leuven Hospital, Belgium.
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In the original 1972 publication of BM [3], the slow GFR
is corrected using a polynomial of the second degree:
Exact GFR ¼0:990778 slowGFRð Þ
0:001218 slowGFRð Þ2;
where both exact GFR and slow GFR are expressed in
ml/min.
As GFR is usually indexed or normalized by the body
surface area (BSA), this exact GFR is further adjusted as
follows:
Exact GFRBSA ¼ Exact GFR1:73BSA ;
where the BSA is usually calculated with the Du Bois and
Du Bois formula [6].
BSA ¼ 0:007184height0:725weight0:425:
BSA is expressed in m2, so finally the exact GFRBSA is
expressed in ml/min/1.73 m2.
As in the original BM publication of 1972 BSA normal-
ization is not even mentioned, correction for BM should
be done first, followed by BSA normalization.
Guidelines for measuring GFR using plasma sampling
[4], adopted by the British Nuclear Medicine Society,
normalize GFR for BSA first before applying the BM
correction. The guideline mentions explicitly that it is
important to perform the BSA and AUC (or BM) cor-
rections in the right order and that this is particularly
important for children in whom the effects of BSA nor-
malization have the largest consequences. The basis for
this statement is unclear, as no reference is cited in
the text.
In a recent technical review, Murray et al. [5] suggested
that BSA normalization be performed before applying the
quadratic BM correction using only a one-compartment
decay, without any scientific argumentation, but with
reference to Picciotto et al. [7]. Furthermore, Murray and
colleagues state that the BM correction is known to
overestimate GFR for patients with a renal clearance of
more than 80ml/min/1.73 m2, particularly for patients
with a BSA below 1m2, which is the case in paediatric
patients. After careful reading of the article by Picciotto
et al. [7] we could not discover the basis for his statement.
Therefore, through this study we aim to determine which
step comes first: BSA normalization or AUC correction.
We performed a theoretical analysis assessing the effect
on exact GFR calculated from the slow GFR when
applying the BM correction first followed by BSA nor-
malization compared with BSA normalization first and
then BM correction. We also investigated whether and
under which circumstances these differences became
clinically important and we used patient data to deter-
mine the correct order of application.
Materials and methods
51Cr-EDTA procedures were performed in 20 patients
aged between 5 and 22 years with Duchenne muscular
dystrophy (DMD). The study was performed in accor-
dance with the ethical standards laid down in the 1964
Declaration of Helsinki and its later amendments.
Consent forms were signed by parents of participants
below 17 years of age or by participants older than
18 years of age. Assent forms were signed by participants
of 5–17 years of age.
From each patient, eight blood samples were collected at
fixed time points (15–30–45–60–120–180–240–300 min
after intravenous bolus injection of 51Cr-EDTA) and the
concentration–time curve was fitted by a double-
exponential decay:
cðtÞ ¼ AeatþBebt :
The exact GFR was calculated from this curve as follows:
Exact GFR ¼ Administered activity
AUC
¼ Administered activityA
aþ Bb
:
The slow GFR was obtained by fitting the concentration
values at 2, 3, 4 and 5 h after injection, as described in [4],
with a monoexponential decay curve:
cðtÞ ¼ Megt ;
SlowGFR ¼ Administered activity
AUC
¼ Administered activityM
g
:
This slow GFR was then corrected in two ways.
(1) BM correction first, followed by BSA normalization:
GFRBM ¼
0:990778 slowGFRð Þ0:001218 slowGFRð Þ2;
GFRBMBSA ¼ GFRBM1:73BSA :
(2) BSA normalization, followed by BM correction:
GFRBSA ¼ SlowGFR1:73BSA ;
GFRBSABM ¼0:990778 GFRBSAð Þ
0:001218 GFRBSAð Þ2:
All statistical analyses, including nonlinear curve fitting,
were performed with GraphPad Prism 6.0 (GraphPad
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Software Inc., La Jolla, California, USA). Paired differ-
ences were tested against zero with the Wilcoxon signed-
rank test.
Results
Theoretical analysis
Mathematically, the difference between the results
obtained with both orders of application can be calculated
as follows:
D ¼ GFRBMBSAGFRBSABM;
D ¼½0:990778 slowGFRð Þ0:001218 slowGFRð Þ2
 1:73
BSA
0:990778 slowGFR 1:73
BSA
 
þ0:001218
 slowGFR 1:73
BSA
 2
:
The linear component is cancelled out, leaving us with
the following quadratic terms:
D ¼0:001218 slowGFRð Þ2 1:73
BSA
þ0:001218
 slowGFRð Þ2 1:73
BSA
 2
;
D ¼ 0:001218 slowGFRð Þ2 1:73
BSA
 
 1 1:73=BSA½ :
The relative difference Δ/[(GFRBM-BSA+GFRBSA-
BM)/2] in terms of BSA and slow GFR is presented in
Table 1. This difference is zero when BSA= 1.73 m2,
independent of the slow GFR value. For 1.4≤BSA
≤ 2.3 m2 and slow GFR< 140 ml/min, the absolute dif-
ferences between both approaches are smaller than 5%
(bold italic in Table 1), which could be considered
clinically insignificant but become significant (>10%)
when BSA is below 1.4 m2 and with increasing slow GFR
(italic in Table 1). In patients with very low BSA
(BSA< 1 m2), the differences become very large, espe-
cially at high slow GFR (slow GFR> 100 ml/min). The
BM-BSA application order may thus have a large effect
for children and adults with extreme low BSA, especially
for high GFR values.
For example, an individual with BSA= 0.6 m2 (average
BSA of a 3-year-old child, with average height of 95 cm
and weight of 14 kg) and slow GFR= 50 ml/min has a
true GFR of 134.1 ml/min/1.73 m2 when the order BM-
BSA is applied and 117.5 ml/min/1.73 m2 when BSA-BM
is applied, resulting in an absolute difference of 16.6 ml/
min/1.73 m2, or a relative difference of 16.6/
[(134.1+ 117.5)/2]= 13.1%.
To give another example, an individual with
BSA= 0.6 m2 and slow GFR= 100ml/min has a true
GFR of 251ml/min/1.73 m2 when the order BM-BSA is
applied and 184 ml/min/1.73 m2 when BSA-BM is used,
an absolute difference of 67 ml/min/1.73 m2, or a relative
difference of 67/217.5= 30.4%.
Glomerular filtration rate measurement in patients with
Duchenne muscular dystrophy
The calculations in the previous section illustrate that
there are significant differences between both methods,
and that it is therefore important to apply the correct
order, especially in patients with low BSA and high slow
GFR. The question still remains as to which order is
correct and should be applied in those patients. DMD
patients are a subgroup of children that reflects this
extreme situation very well (Table 2). We used their
GFR data to determine the correct order of applying the
BM correction and BSA normalization.
Table 1 Relative difference % Δ/[(GFRBM-BSA+GFRBSA-BM)/2], for different values of slow glomerular filtration rate (ml/min) and body
surface areas (m2)
BSA (m2)
0.5 0.6 0.7 0.8 0.9 1 1.1 1.2 1.3 1.4 1.5 1.6 1.73 1.8 1.9 2.0 2.1 2.2 2.3 2.4
Slow GFR (ml/min)
10 3.1 2.4 1.8 1.5 1.2 0.9 0.7 0.6 0.4 0.3 0.2 0.1 0.0 0.0 − 0.1 − 0.2 − 0.2 − 0.3 − 0.3 − 0.3
20 6.4 4.9 3.8 3.0 2.4 1.9 1.5 1.1 0.8 0.6 0.4 0.2 0.0 −0.1 − 0.2 − 0.3 − 0.4 − 0.5 − 0.6 − 0.7
30 9.9 7.5 5.8 4.6 3.6 2.8 2.2 1.7 1.3 0.9 0.6 0.3 0.0 −0.1 − 0.3 − 0.5 − 0.7 − 0.8 − 0.9 − 1.1
40 13.6 10.2 7.9 6.2 4.9 3.8 3.0 2.3 1.7 1.2 0.8 0.4 0.0 −0.2 − 0.5 − 0.7 − 0.9 − 1.1 − 1.3 − 1.4
50 17.5 13.1 10.1 7.9 6.2 4.9 3.8 2.9 2.2 1.6 1.0 0.5 0.0 −0.3 − 0.6 − 0.9 − 1.1 − 1.4 − 1.6 − 1.8
60 21.7 16.2 12.4 9.7 7.6 6.0 4.7 3.6 2.7 1.9 1.2 0.6 0.0 −0.3 − 0.7 − 1.1 − 1.4 − 1.7 − 2.0 − 2.2
70 26.2 19.5 14.9 11.6 9.1 7.1 5.5 4.2 3.2 2.2 1.5 0.8 0.0 −0.4 − 0.8 − 1.3 − 1.6 − 2.0 − 2.3 − 2.6
80 31.0 22.9 17.4 13.5 10.6 8.3 6.4 4.9 3.7 2.6 1.7 0.9 0.0 −0.4 − 1.0 − 1.5 − 1.9 − 2.3 − 2.7 − 3.0
90 36.1 26.5 20.1 15.6 12.2 9.5 7.4 5.6 4.2 3.0 1.9 1.0 0.0 −0.5 − 1.1 − 1.7 − 2.2 − 2.6 − 3.0 − 3.4
100 41.7 30.4 23.0 17.7 13.8 10.8 8.4 6.4 4.7 3.4 2.2 1.1 0.0 −0.5 − 1.2 − 1.9 − 2.4 − 3.0 − 3.4 − 3.8
110 47.6 34.5 26.0 20.0 15.5 12.1 9.4 7.2 5.3 3.8 2.4 1.3 0.0 −0.6 − 1.4 − 2.1 − 2.7 − 3.3 − 3.8 − 4.3
120 54.1 38.9 29.2 22.4 17.3 13.5 10.4 7.9 5.9 4.2 2.7 1.4 0.0 −0.7 − 1.5 − 2.3 − 3.0 − 3.6 − 4.2 − 4.7
130 61.1 43.6 32.5 24.9 19.2 14.9 11.5 8.8 6.5 4.6 3.0 1.6 0.0 −0.7 − 1.7 − 2.5 − 3.3 − 4.0 − 4.6 − 5.2
140 68.7 48.7 36.1 27.5 21.2 16.4 12.7 9.6 7.1 5.0 3.2 1.7 0.0 −0.8 − 1.8 − 2.8 − 3.6 − 4.3 − 5.0 − 5.6
150 77.0 54.1 39.9 30.3 23.3 18.0 13.8 10.5 7.8 5.5 3.5 1.9 0.0 −0.9 − 2.0 − 3.0 − 3.9 − 4.7 − 5.5 − 6.1
Italic, |difference|≥10%; bold roman, |difference|≥5% and <10%; bold italic, |difference|<5%.
BSA, body surface area; GFR, glomerular filtration rate.
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Figure 1 displays exact GFR and slow GFR values of 20
DMD patients before BSA normalization and illustrates
that the GFR values of DMD patients are close to the
BM correction line, proving the validity of the BM cor-
rection. Figure 2 shows exact GFR and slow GFR values,
normalized to BSA. Applying BSA normalization first in
this population results in higher values of both slow and
exact GFR, extending the range of GFR values from
160 ml/min in Fig. 1 to 280 ml/min/1.73 m2 in Fig. 2.
Figure 2 also shows a larger offset from the BM correction
line, as compared with Fig. 1.
The relative differences between GFR values, calculated
from the slow GFR for both application orders (BM-BSA vs.
BSA-BM), and exact GFR values are presented in Fig. 3. The
median of paired differences between both methods is 5.50%
(P<0.0001). The median GFR calculated from the BM-BSA
order deviated only −0.05% from the double-exponentially
calculated exact GFR (P>0.05), and a deviation of 5.40% was
found between the exact GFR and the GFR obtained from
the BSA-BM application order (P=0.0006).
Discussion
GFR can be determined accurately by measuring the rate
of radiotracer clearance from blood using a simplified
sampling strategy that is convenient in daily clinical
practice, given that the necessary corrections are applied
in the right order. The British guidelines [4] for mea-
suring GFR recommends that the BM equation can be
used but ‘if the BM correction is used then it is important
that the BSA and AUC corrections are applied in the right
order. This is particularly important for results in children
when the effects of the BSA correction are greatest’.
According to these guidelines, BSA indexing should be
applied first, followed by BM correction. However, in this
study in DMD patients, we showed that this order should
be reversed and that the correct order of application is
BM correction before BSA normalization.
Table 2 Characteristics of 20 Duchenne muscular dystrophy
patients
Mean (SD) Range
Age (years) 14.7 (4.0) 5–22
BSA (m2) 1.33 (0.27) 0.74–1.75
Exact GFR (ml/min/1.73 m2) 137.0 (29.1) 85.7–226.3
GFRBM-BSA (ml/min/1.73 m
2) 138.1 (34.3) 75.8–236.7
GFRBSA-BM (ml/min/1.73 m
2) 127.9 (23.4) 75.8–181.9
BM, Bröchner-Mortensen; BSA, body surface area; GFR, glomerular
filtration rate.
Fig. 1
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Apart from our data, other justifications for the reversal of
the order can be found in the literature. First, the original
BM article [3] mentions slow and exact GFR expressed in
ml/min. BSA indexing is not discussed in this article.
Second, the original BM correction formula (0.990778×
slow GFR− 0.001218× slow GFR2) [3] is built with data
ranging from 10 to 170ml/min for slow GFR, resulting in
exact GFR values ranging between 10 and 140ml/min. By
first applying BSA indexing for extremely low BSA values,
the indexed slow GFR is out of the original range,
requiring extrapolation, a common statistical mistake.
There is no reason to assume that the relationship would
continue much beyond the range of the data. Predictions
substantially beyond that range are likely to be very wrong.
Jødal and Brøchner-Mortensen [8] state that one cannot
obtain clearance values higher than about 200ml/min using
the BM correction formula. They further mention that on
using second-order polynomials the reference clearance is
increasingly underestimated at high clearance values (on
average 10% at 175ml/min/1.73m2) [9]. However, it
should be noted that the maximum value of 200ml/min
corresponds with a slow GFR of 406.7ml/min
[= 0.990778/(2× 0.001218)], a value that is more than
double the range of the original BM correction formula,
and a value so high that it has never been reported before.
Further, the value of 175ml/min/1.73m2 is outside the
range of the original BM correction formula. Application of
the BM correction formula should be restricted to the range
0–170ml/min for the slow GFR. This corresponds to a
range for the true GFR of 0–133ml/min. When the slow
GFR is out of range, there is no other possibility than
obtaining the complete concentration–time decay, includ-
ing the fast component. One should never rely on extra-
polation. In Fig. 1, we illustrate that the BM correction is
still applicable for DMD patients when applied on the slow
GFR expressed in ml/min, but the deviation from the BM
equation becomes large (Fig. 2) when applied to the BSA-
indexed slow GFR. As all slow GFR values for our DMD
population were still within the original range of the BM
equation (largest slow GFR was 154ml/min), application of
this correction formula does not require extrapolation, only
interpolation. When applied to the BSA-normalized values,
five of 20 patients had BSA-normalized slow GFR values
larger than 170ml/min/1.73m2 (the largest slow GFR was
280ml/min/1.73m2), requiring dangerous extrapolation.
The nonradioactive agent iohexol has become more
standard for direct GFR measurements, because it is
readily available, accepted in the USA, and not secreted,
metabolized or reabsorbed by the kidney. Schwartz et al.
[2] presented a BM-like correction formula when deter-
mining the slow GFR from the iohexol measurement,
being of the same quadratic form with rather equivalent
coefficients. However, Schwartz and colleagues applied
BSA-normalized exact and slow GFR values during the
construction of his correction equation, thus extending
the range of application of his correction formula. In his
equation, the order BSA-BM can be applied. Again,
however, the correction formula should be applied within
the original range of the data. It should be noted that, in
his study, a median slow GFR of 60.83 ml/min, with a
third quartile of 97.53 ml/min, and a median BSA of
1.66 m2, with a first quartile of 1.31 m2 were reported. As
shown in Table 1, a slow GFR of 100 ml/min would
require a BSA less than 1.1 m2 to see a difference of 10%
or more between both orders of BM/BSA application.
Piepsz and Ham [10] and Murray et al. [5] have previously
warned about using BM correction for high clearance
values because this correction underestimates GFR
values greater than 100 ml/min/1.73 m2 and introduces
considerable compression of the clearance values higher
than 140ml/min/1.73 m2. Monitoring of hyperfiltration
will therefore be seriously hampered by using this cor-
rection factor. Piepsz, however, uses GFR values
expressed in ml/min/1.73 m2 and not in ml/min and refers
to the article of BM published in 1974 [11], not to the
original article of 1972 [3]. As mentioned before, in the
original article of 1972, the BM correction formula is
presented for slow and true GFR in ml/min, but in 1974
BM applied his original formula for BSA-normalized
GFR, expressed in ml/min/1.73 m2. Especially for chil-
dren with small BSA, the consequence of normalizing
first is that the slow GFR (expressed in ml/min/1.73 m2)
is outside the application range. From our study, we can
conclude that the underestimation of the exact GFR is
larger when BSA-BM is applied (median= ± 5%), com-
pared with application of BM-BSA (median= ± 0%)
(Fig. 3). In the article of 1974, BM [11] reported per-
forming BSA indexing for slow GFR first followed by a
correction to compensate for the underestimation of the
AUC in 30 children suffering from nephrourological dis-
orders, and this might be the basis for the current BSA-
BM order recommendation. In that article, the equation
GFR= 1.01× slow GFR− 0.0017× (slow GFR)2 has
been presented for children, where exact and slow GFR
values are both expressed in ml/min/1.73 m2. However,
the range of application in his study extended from 0 to
160 ml/min/1.73 m2, which is much smaller than what we
need here for our DMD patients (Fig. 2). The children in
the 1974 article of BM all had GFR values lower than
120 ml/min/1.73 m2, and consequently the difference
between both application orders (BM-BSA or BSA-BM)
is small (usually smaller than 5%) in this population.
It is clear from our present study that the order of
applying BM correction and BSA indexing is important
for extreme patient populations having a low BSA and a
high slow GFR, which is valid for DMD patients. The
correct order of application in this population should be
BM correction first followed by BSA normalization, and
not vice versa. The order of application is of less impor-
tance for people with normal BSA (>1.4 m2) and/or nor-
mal GFR, where the difference will be mostly less than
5%, which is clinically acceptable.
Bröchner-Mortensen and body surface area correction Pottel et al. 5
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